We serve Chemical Name:7-bromoquinolin-8-ol CAS:13019-32-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:7-bromoquinolin-8-ol
CAS.NO:13019-32-4
Synonyms:7-Bromo-8-quinolinol;7-bromo-quinolin-8-ol;7-Brom-chinolin-8-ol;7-Bromo-8-hydroxyquinoline;8-quinolinol,7-bromo
Molecular Formula:C9H6BrNO
Molecular Weight:224.05400
HS Code:2933499090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:33.12000
Exact Mass:222.96300
LogP:2.70290
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:NONH for all modes of transpor
Packing Group:
Contact us for information like 7-Bromo-8-quinolinol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,8-quinolinol,7-bromo physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,8-quinolinol,7-bromo Use and application,8-quinolinol,7-bromo technical grade,usp/ep/jp grade.
Related News: A combination of Imbruvica and AbbVie and Roche’s Venclexta slashed the risk of cancer progression or death by 78.4% compared with a cocktail of Roche’s Gazyva and the chemotherapy chlorambucil in previously untreated CLL. The data, from the phase 3 GLOW trial, were shared at the European Hematology Association (EHA) annual meeting. 7-bromoquinolin-8-ol manufacturer The entire set of results “strongly support” the Darzalex-Rd combo as a new standard of care for newly diagnosed, transplant-ineligible multiple myeloma patients, Thierry Facon, M.D., an investigator of the MAIA trial, said in a statement. 7-bromoquinolin-8-ol supplier With the global industrial division of labor and the change in the business model of multinational pharmaceutical companies, the outsourced market for patented drug substances will further expand. 7-bromoquinolin-8-ol vendor On the basis of achieving low-cost and high-quality processes, production capacity will become the core driving force for API companies to break through sales bottlenecks. 7-bromoquinolin-8-ol factory The entire set of results “strongly support” the Darzalex-Rd combo as a new standard of care for newly diagnosed, transplant-ineligible multiple myeloma patients, Thierry Facon, M.D., an investigator of the MAIA trial, said in a statement.
